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Abstract: Serrated polyps (SPs) of the colorectum pose a novel challenge to practicing gas-
troenterologists. Previously thought benign and unimportant, there is now compelling evidence 
that SPs are responsible for a significant percentage of incident colorectal cancer worldwide. 
In contrast to conventional adenomas, which tend to be slow growing and polypoid, SPs have 
unique features that undermine current screening and surveillance practices. For example, ses-
sile serrated polyps (SSPs) are flat, predominately right-sided, and thought to have the potential 
for rapid growth. Moreover, SSPs are subject to wide variations in endoscopic detection and 
pathologic interpretation. Unfortunately, little is known about the natural history of SPs, and 
current guidelines are based largely on expert opinion. In this review, we outline the current 
taxonomy, epidemiology, and management of SPs with an emphasis on the clinical and public 
health impact of these lesions.
Keywords: serrated polyp, sessile serrated adenoma, sessile serrated polyp, traditional serrated 
adenoma, hyperplastic polyp, epidemiology, colonoscopy
Introduction
Colorectal cancer (CRC) remains the second leading cause of cancer-related mortality 
in the US despite widespread screening protocols.1 Importantly, serrated polyps (SPs) 
have been identified as a unique pathway to CRC that may account for up to 35% of 
sporadically occurring CRCs.2 These lesions have distinct molecular features that set 
them apart from the traditional “Fearon–Vogelstein” or “adenoma–carcinoma” model 
of tumorigenesis.3 In contrast to conventional adenomas, premalignant SPs are more 
prevalent in females, more frequently located in the proximal colon, and carry a novel 
genetic signature characterized by BRAF mutations, CpG island methylation, and 
microsatellite instability.4 Of particular concern, serrated pathway cancers represent 
a disproportionate number of interval CRC (i.e., cancers occurring after a negative 
screening test) and have appropriately become a target of public health investigation.5
The purpose of this review is to provide an overview of the taxonomy, epidemiol-
ogy, and management of SPs.
Overview of SPs
History
Much of the uncertainty surrounding SPs is driven by the fact that, historically, these 
polyps were all classified as hyperplastic polyps (HPs) and were considered innocu-
ous, without malignant potential, and thus clinically unimportant. However, a series 
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of case reports in the 1970s and 1980s began to question this 
long-held convention.6,7 The term “serrated adenoma” was 
officially coined in 1990 when Longacre and Fenoglio-Preiser 
used the name to characterize a series of premalignant lesions 
that had a “serrated glandular pattern simulating that seen 
in hyperplasia”.8 Further progress was made in 2008, when 
Torlakovic et al successfully differentiated sessile serrated 
polyps (SSPs) and traditional serrated adenomas (TSAs) 
on the basis of crypt architecture and molecular markers, 
setting the groundwork for modern classification systems.9 
Currently, the World Health Organization (WHO) recognizes 
three major types of SPs: HPs, SSPs, and TSAs10 (Figure 1).
Taxonomy and histology
HPs
HPs are the most indolent of SPs and are characterized by 
straight crypts that rise perpendicularly from the muscularis 
mucosae. HPs have a jagged infolding crypt epithelium that 
is more pronounced near the luminal surface, which gives 
them a “serrated” appearance11 (Figure 2A). Endoscopi-
cally, these lesions are smooth, symmetric, pale, and tend 
to be distally located12 (Figure 2B). HPs are subclassified 
histologically by the mucin content of their epithelial cells. 
Microvesicular hyperplastic polyps (MVHPs) exhibit cells 
with vacuolated cytoplasm containing numerous small 
mucin droplets. Goblet cell hyperplastic polyps (GCHPs) are 
composed almost entirely of goblet cells with large mucin-
containing apical vesicles, and mucin-poor HPs have scant 
cytoplasmic mucin.13
SSPs
SSPs are distinguished from HPs by crypt distortion.9,14 
In these lesions, the zone of proliferation migrates to the 
side of the crypt, causing disorganization and dilatation of 
crypt architecture.2 Classically, these configurations are 
referred to as “boot” or “anchor-shaped” crypt bases2,15,16 
(Figure 2C). On endoscopic examination, SSPs tend to 
be pale, larger than 5 mm, flat or only slightly raised, and 
smooth with irregular borders17–19 (Figure 2D). Many of 
these lesions excrete excessive quantities of mucin and 
are often covered with a thin, yellow, mucinous cap and/or 
surrounded by a “rim of debris”.19 Of note, there is some 
controversy about the terminology for these lesions, and 
other authors use different terms such as sessile serrated 
adenoma (SSA), SSA or SSP, or sessile serrated lesion 
(SSL). Herein, we use the term SSP to avoid confusion with 
conventional adenomas.
Serrated polyps of the colorectum
HP
MVHP GCHP MPHP
SSP TSA
Figure 1 Serrated polyps of the colorectum.
Abbreviations: GCHP, goblet cell hyperplastic polyp; HP, hyperplastic polyp; 
MPHP, mucin-poor hyperplastic polyp; MVHP, microvesicular hyperplastic polyp; 
SSP, sessile serrated polyp; TSA, traditional serrated adenoma.
A C E
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Figure 2 Endoscopic and histologic appearance of serrated polyps including (A, B) a microvesicular hyperplastic polyp, (C, D) sessile serrated polyp, and (E, F) traditional 
serrated adenoma.
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Sessile serrated polyps with dysplasia (SSPDs) have 
similar crypt architecture and gross appearance to SSPs, 
but have dysplastic features including pseudostratification, 
hyperchromatic nuclei, and mitotic figures.20 Approximately 
15% of SSPs will have dysplastic features, and these lesions 
disproportionately affect women.15
TSAs
Of all SPs, TSAs are the least prevalent, representing approxi-
mately 1% of SPs.15 Histologically, they represent a hybrid 
of serrated and conventional adenomas with “sawtooth” 
crypts haphazardly arranged in a tubulovillous pattern19,21 
(Figure 2E). The defining feature of TSAs is ectopic crypt 
formation. Ectopic crypts lose their orientation to the mus-
cularis mucosae and branch out at obtuse angles, creating 
villous projections into the lumen of the large intestine.2,21 
A significant number of these lesions are frankly dysplastic 
and capable of malignant transformation, albeit through a 
different molecular pathway than SSPs.4,8,22 As TSAs are 
typically more polypoid in form and located within the dis-
tal colorectum, they are more easily detected on endoscopy 
than SSPs23,24 (Figure 2F). All participants provided written 
informed consent for this study including publication of 
photography and image captured during colonoscopy.
The molecular pathways of serrated 
carcinogenesis
Conventional adenomas arise by the accumulation of a well-
studied sequence of mutations involving APC, KRAS, and 
p53.25 As the malignant potential of SPs has only recently 
been appreciated, the molecular underpinnings of serrated 
carcinogenesis are the subject of active research. From this, 
two primary pathways are emerging.
SSP pathway
A mutation in the BRAF oncogene is thought to be the incit-
ing event of the SSP pathway4 (Figure 3). When present, 
BRAF mutations trigger downregulation of apoptosis and 
BRAF mutation Normal mucosa
MVHP *GCHP
TSASSPCpG islandmethylation
CpG island
methylation
MLH1
methylation
SSP w/cytological
dysplasia
MSI carcinoma MSS carcinoma
CIMP-variableCIMP-high
TSA w/conventional
dysplasia
MGMT
methylation
Serrated carcinogenesis
KRAS and/or BRAF mutation
Figure 3 Serrated carcinogenesis.
Notes: *While GCHPs are theorized to be the precursor of TSAs, this link has not been definitively proven. Dashed arrows represent possible, but unproven steps.
Abbreviations: CIMP, CpG island methylation phenotype; GCHP, goblet cell hyperplastic polyp; MSI, microsatellite instable; MSS, microsatellite stable; MVHP, microvesicular 
hyperplastic polyp; SSP, sessile serrated polyp; TSA, traditional serrated adenoma.
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promote cellular proliferation.26 Secondly, hypermethylation 
of promoter regions causes epigenetic silencing of key regu-
latory genes.27,28 While some degree of methylation is pres-
ent in nearly all types of cancer, serrated neoplasms in this 
pathway demonstrate global methylation of CpG islands and 
are thus classified as CpG island methylation phenotype-high 
(CIMP-H).29 Epigenetic silencing of MLH1, a critical DNA 
mismatch repair gene, is thought to trigger the microsatel-
lite instability (MSI) seen in serrated adenocarcinoma.30,31 
As MVHPs have high rates of BRAF mutations, they are the 
favored precursors of SSPs.32,33 From this stage, increasing 
levels of epigenetic silencing facilitate progression to SSPD 
and, ultimately, MSI-High (MSI-H) CRC.4,34,35
TSA pathway
The mechanism by which TSAs progress to CRC is less 
well understood, but has important differences with the SSP 
pathway (Figure 3). To begin with, TSAs are much more 
genetically diverse than SSPs. They may or may not have 
BRAF mutations and can be either CIMP-H or CIMP-low.22 
Of importance, TSAs do have a high frequency of KRAS 
mutations, a key oncogene implicated in many types of 
malignancy, including the traditional adenoma–carcinoma 
sequence.22,36,37 Initially, activating KRAS and/or BRAF muta-
tions causes uncontrolled cellular proliferation.4,38 Epigenetic 
silencing of the DNA repair gene MGMT then allows for the 
accumulation of subsequent mutations, ultimately leading to 
a subtype of CRC that is microsatellite stable.39 As GCHPs 
have higher frequencies of KRAS mutations, they are hypoth-
esized to be the precursors to TSAs, although no definitive 
link has been elucidated.35 Given the genetic and phenotypic 
diversity of TSAs, it has been proposed that multiple distinct 
pathways exist.40
Serrated polyposis syndrome (SPS)
SPS is a phenotypically diverse condition characterized by 
multiple concurrent SPs. The WHO defines SPS as: 1) at least 
five SPs proximal to the sigmoid colon, at least two of which 
are >10 mm in diameter; 2) any number of SPs occurring 
proximal to the sigmoid colon in an individual with a first-
degree relative who has been diagnosed with SPS; or 3) >20 
SPs of any size throughout the colon of a single individual.10 
Based on a series of case studies, males and females appear 
to be equally affected and the mean age at presentation is in 
the sixth decade of life.41 While the true incidence of CRC 
in SPS is unknown, estimates from small case series are as 
high as 70%.42–44 Also, importantly, first-degree relatives of 
those who carry a diagnosis of SPS have an increased risk 
of CRC.45 There is growing evidence of a genetic etiology 
of SPS, but no proven hereditary basis, and routine genetic 
testing is not currently recommended.46–48 More research is 
needed to separate what is likely a number of molecularly 
distinct disease processes.
Epidemiology of SPs
Prevalence
Population-based studies estimate that roughly 40% of adults 
harbor at least one SP.17,33,49 Of these, HPs are by far the 
most common, representing 70%–90% of SPs.17,33,50 SSPs 
(10%–25%) and TSAs (~1%) make up a smaller proportion 
of SPs, respectively.15,17,33,51
The prevalence of SSPs is estimated to be anywhere 
between 2% and 15% in average risk patients.15,17,52,53 How-
ever, the true prevalence may be even higher, as SPs are 
often subtle and likely underdetected on routine colonoscopy. 
The median age at presentation of SSPs is 61,15 and they 
are at least as common in females as males.15,33 In contrast 
to HPs, SSPs are predominately located on the right side of 
the colon.15,33,50
Risk factors
Much of the epidemiologic data on serrated colorectal lesions 
predate the current classification system. However, important 
risk factors have emerged. Tobacco, alcohol, and obesity 
have consistently been identified as risk factors for SPs.54–60 
These results were recently confirmed in a meta-analysis by 
Bailie et al, which reported increased risk for tobacco smok-
ing (relative risk [RR], 2.47; 95% confidence interval [CI], 
2.12–2.87), alcohol intake (RR, 1.33; 95% CI, 1.17–1.52), 
and body mass index (RR, 1.40; 95% CI, 1.22–1.61) when 
comparing the highest and lowest categories of exposure.61 
While studies on protective factors are mixed,55,58,59 pooled 
data suggest that nonsteroidal anti-inflammatory drug use 
as well as diets high in folate, calcium, or fiber significantly 
reduce the risk of SPs.61 Interestingly, Caucasians appear to 
have a higher prevalence of SPs than do African-Americans 
or Hispanics.62
With regard to SSPs, multiple studies have documented 
female sex as a significant risk factor15,33,51 (Table 1). Aggre-
gate data on modifiable risk factors from Bailie et al suggest 
that smoking and alcohol are more strongly associated with 
SSPs than SPs as a whole.61 The role of obesity is less clear, 
and the available data are conflicting.59,61,63 A recent study 
by Davenport et al identified diets high in red meat and fat 
as important risk factors for SSPs, while simultaneously 
reporting that folate and fiber have a protective effect.64 
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Table 1 Summary of literature on the risk factors for SSPs, including data from individual studies and meta-analysis where available
Risk factors Studies, (n SSPs) Results (OR/RR/IDRa [95% CI])
Age Anderson et al,63 (n=90) Per year increase: 1.05 (1.02–1.08)
Buda et al,52 (n=23) <50 years: 1.00 (ref)
50–69 years: 5.8 (1.3–26.8)
≥70 years: 9.3 (1.9–45.4) 
Burnett-Hartman et al,59 (n=149) <50 years: 1.00 (ref)
50–59 years: 1.63 (0.72–3.67)
60–69 years: 2.09 (0.87–5.00)
≥70 years: 2.19 (0.83–5.76)
Hetzel et al,17 (n=46) Per year increase: 1.00 (0.96–1.03)
Sex Burnett-Hartman et al,59 (n=149) Male: 1.00 (ref)
Female: 1.37 (0.82–2.28)
Hetzel et al,17 (n=46) Female: 1.00 (ref)
Male: 1.55 (0.93–2.61)
Lash et al,15 (n=2416) Male: 1.00 (ref)
Female: 1.21 (1.11–1.32)
Race Burnett-Hartman et al,59 (n=149) White: 1.00 (ref)
African-American: 0.21 (0.02–2.14)
Asian/Pacific Islander: 1.33 (0.54–2.44) 
Socioeconomic status Burnett-Hartman et al,59 (n=149) High school or less: 1.0 (ref)
Some college: 2.60 (1.08–6.24)
College graduate: 3.35 (1.41–7.99)
Graduate degree: 3.63 (1.55–8.54)
FH of CRC Burnett-Hartman et al,59 (n=149) No FH: 1.00 (ref)
FH: 1.54 (0.97–2.43)
Smoking Bailie et al,61 meta-analysis Never smoker: 1.00 (ref)
Current/ever smoker: 3.40 (1.90–6.07)
Alcohol Bailie et al,61 meta-analysis Low alcohol intake: 1.00 (ref)
Higher/highest alcohol intake: 1.85 (1.03–3.32)
Obesity Bailie et al,61 meta-analysis Low BMI: 1.00 (ref)
BMI ≥ 30: 1.31 (0.89–1.92)
Physical activity Bailie et al,61meta-analysis Low physical activity: 1.00 (ref)
High physical activity: 0.80 (0.43–1.48)
Diabetes Anderson et al,63 (n=90) Nondiabetic: 1.00 (ref)
Diabetic: 4.57 (2.36–8.82)
Fiber intake Davenport et al,64 (n=214) Low fiber (<13 g/day): 1.00 (ref)
High fiber (>25 g/day): 0.46 (0.19–0.68) 
Dietary folate Davenport et al,64 (n=214) Low folate (<395 mg/day): 1.00 (ref)
High folate (>812 mg/day): 0.51 (0.26–0.98)
Calcium intake Davenport et al,64 (n=214) Low calcium (<596 mg/day): 1.00 (ref)
High calcium (>1217 mg/day): 0.54 (0.28–1.06)
Fat intake Davenport et al,64 (n=214) Low fat (<48 g/day): 1.00 (ref)
High fat (>98 g/day): 3.09 (1.24–7.72)
Red meat intake Davenport et al,64 (n=214) Low red meat (<16 g/day): 1.00 (ref)
High red meat (>73 g/day): 3.38 (1.90–6.00)
NSAIDs Bailie et al,61 meta-analysis Low/no use: 1.00 (ref)
Regular/current use: 0.62 (0.42–0.92)
HRT Bailie et al,61 meta-analysis Nonuser: 1.00 (ref)
User: 1.41 (0.82–2.41)
Notes: Bolded results indicate statistical significance, amultivariate OR reported when provided.
Abbreviations: BMI, body mass index; CI, confidence interval; Ref, reference; CRC, colorectal cancer; FH, family history; IDR, incidence density ratio; OR, odds ratio; RR, 
relative risk; SSPs, sessile serrated polyps; NSAIDs, nonsteroidal anti-inflammatory drugs; HRT, hormone replacement therapy.
Interestingly, Burnett-Hartman et al found an independent 
association between a higher level of education and SSPs, but 
whether this represents a true association or is confounded by 
other factors (e.g., differences in bowel preparation) has yet to 
be resolved.59 Given their relative scarcity, there is a paucity 
of data on TSAs and their risk factors are largely unknown.
When interpreting epidemiologic studies on SPs, it is 
important to remember that early investigations did not 
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 differentiate between subtypes of SPs, and even more recently 
reported data are hindered by pathologic misclassification, 
particularly the distinction between large proximal HPs and 
SSPs.
Natural history
True HPs, especially those that are small and located in 
the distal colon and rectum, are thought to have little or no 
malignant potential.20 However, MVHPs and GCHPs may 
serve as important intermediaries in serrated carcinogenesis, 
as previously discussed.
In contrast, there is substantial evidence that both SSPs 
and TSAs have malignant potential. Various studies have 
documented foci of high-grade dysplasia and/or invasive 
adenocarcinoma developing within these lesions.15,16,65 
Moreover, there are multiple case reports of SSPs found 
adjacent to MSI-H colorectal tumors.66–68 Overall, the rate of 
high-grade dysplasia in SSPs ranges from 1% to 16%,24,69–73 
and it is estimated that around 6% of SSPs will develop into 
MSI-H CRC.74
Of great debate is the concept of dwell time or the rate at 
which SSPs progress to CRC. Multiple observational studies 
have shown higher rates of serrated cancers than SSPDs, sug-
gesting a rapid transition phase or a relatively truncated dwell 
time.34,75,76 Also, there are a few case reports of SSPs left in 
situ transforming into invasive CRC in less than a year.77,78
Alternatively, Lash et al reported that the median age of 
patients with SSPs, SSPDs, and SSPs with foci of adeno-
carcinoma was 61, 66, and 76 years, respectively.15 The 
authors concluded that these results imply a slow, stepwise 
progression along the pathway of serrated carcinogenesis 
over a period of 15+ years. In addition, a retrospective case 
series of MSI-H carcinoma diagnosed at the site of previous 
polypectomy reported a mean of 7.3 years between initial 
polypectomy and cancer resection.16
Importantly, these studies are limited by the fact that 
SSPs are notoriously difficult to detect on endoscopy, are 
often incompletely resected, and were historically thought 
benign and unimportant. The true behavior of SSPs in vivo 
is extremely challenging to study for ethical and logistical 
reasons. Nevertheless, optimal screening algorithms demand 
a better understanding of the natural history of SPs and SSPs, 
in particular.
The risk of synchronous and metachronous 
neoplasia
SPs increase the risk for both synchronous (concurrent) 
and metachronous (future or interval) neoplasia. In a 
 cross-sectional analysis involving nearly 5000 patients, Li et 
al found that the presence of large (>10 mm) SPs was a strong 
predictor of synchronous advanced colorectal neoplasia (odds 
ratio [OR], 3.24; 95% CI, 2.05–5.13).79 These results were later 
reinforced by two large multicenter studies reporting similar 
risks of synchronous neoplasia associated with large SPs.80,81 
With respect to metachronous lesions, Schreiner et al reported 
an elevated risk of future advanced neoplasia in patients with 
proximal SPs on baseline colonoscopy (OR, 3.14; 95% CI, 
1.59−6.20).80 As previously highlighted, many of these large 
and/or proximal SPs would now be classified as SSPs.
Using the current pathologic classification, Hazewinkel 
et al82 and Ng et al83 found increased risk for synchronous 
advanced neoplasia in large and proximal HPs as well as SSPs. 
These results were confirmed by a large, population-based 
case–control study from Denmark, which highlighted the risk 
for metachronous CRC in patients with SSPs, particularly 
those located in the proximal colon (OR, 12.42; 95% CI, 
4.88–31.58).84 A recent article by Melson et al suggests that 
the risk of metachronous advanced neoplasia in low-risk SPs is 
comparable to that of high-risk tubular adenomas.85 Moreover, 
small observational studies estimate the risk of metachronous 
CRC in patients harboring SSPs to be as high as 12.5%.86,87
Rates of synchronous and metachronous SSPs also appear 
to be elevated,87,88 and the observation that metachronous 
SSPs may be limited to those with preexisting SPs suggests 
a “field effect” phenomenon even in patients who do not 
meet the formal criteria for SPS.88 Meanwhile, for those who 
carry a diagnosis of SPS, the presence of SSPDs, advanced 
adenomas, or combined WHO phenotypes 1 and 3 appears 
to increase the risk for CRC.89
Taken together, these studies suggest that the risk of 
advanced neoplasia increases as one moves from distal to 
proximal colon, from small to large polyp size, and from HP 
to more advanced serrated lesions such as SSPs and TSAs. 
Due to these complexities, many experts have advocated for 
surveillance intervals specific to SPs.
Detection of SPs
Endoscopic detection
Notably, there is significant variation in the endoscopic 
detection rates of SPs (0%–22%) even among experienced 
gastroenterologists,17,90,91 and those practicing today may miss 
more than half of the SPs.17,90 Adequate bowel preparation is 
associated with better detection of flat lesions, in general, and 
SSPs, in particular.92,93 This stands to reason, given their subtle 
endoscopic appearance and typical location in the right colon, 
which is more often affected by suboptimal bowel cleansing. 
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Wijkerslooth et al showed that SSP detection rates were also 
associated with withdrawal times.91 Kahi et al found that the 
detection rate of SPs is correlated to that of conventional 
adenomas.90 However, despite this correlation, it should be 
noted that there are endoscopists with high adenoma detection 
rates and low SSP detection rates and vice versa; this implies 
that overlapping, but not interchangeable skills are needed to 
detect clinically important SPs. Fortunately, the detection rate 
of SPs appears to be increasing over time, as their clinical 
significance gains recognition by endoscopists and patholo-
gists alike.17 An emphasis on tracking the adequacy of bowel 
preparation, cecal intubation rates, and polyp detection rates 
is helping to bridge disparities in practice.94
Alternative methods for detection
Standard colonoscopy is superior to other readily avail-
able CRC screening modalities in detecting SPs, as the 
use of blood-based stool tests, flexible sigmoidoscopy, and 
computed tomography (CT) enterography have obvious 
limitations. To begin with, SSPs are less likely to undergo 
spontaneous hemorrhage14,95 and their relatively low profile 
decreases the probability of trauma-associated injury.96 
Visualization of SSPs on CT enterography is complicated by 
their sessile or flat morphology, and flexible sigmoidoscopy 
simply does not reach the right side of the colon where SSPs 
predominate. In support of this, Chang et al found that fecal 
immunochemical testing (a more specific test of fecal occult 
blood from colonic source) has poor sensitivity for detect-
ing even large SSPs.97 A recent randomized controlled trial 
(RCT) comparing standard colonoscopy to CT colonography 
reported a superior SSP detection rate (4.3% vs. 0.8%) in 
the standard colonoscopy arm,98 and Kahi et al revealed that 
more than half of the proximal advanced SPs had no distal 
lesions, highlighting the limitations of flexible sigmoidoscopy 
in CRC surveillance.99
Of interest, fecal DNA studies have shown promise as 
a novel tool for CRC screening.100,101 While these assays 
reliably detect CRC, their sensitivity for SSPs >10 mm is in 
the range of 42%–66%.100,102,103 Fecal DNA tests are limited 
by their lack of molecular markers specific to serrated neo-
plasms, poor specificity when compared to other noninvasive 
tests (i.e., fecal immunochemical testing), and the need for 
follow-up invasive testing for positive results. Notwithstand-
ing, preliminary studies of BRAF stool assays have shown 
potential,104 leaving the door open for the development of 
fecal DNA tests with higher sensitivity for precancerous SPs.
Highlighting concerning areas of mucosa with dye, a 
technique known as chromoendoscopy, has proven to be a 
useful tool in the detection of SPs.19,33 Multiple studies have 
demonstrated that this technique can improve detection of 
both conventional adenomas and SPs.105–108 However, use of 
chromoendoscopy substantially lengthens procedure times, 
which is the major limitation of this technique and under-
mines its usefulness as a screening modality. In the largest 
RCT to date, Kahi et al reported a modest increase in the 
detection of flat and small adenomas in the chromoendos-
copy arm. However, specific data on SSP detection were not 
reported, and the authors concluded that the additional yield 
was modest and did not justify the routine use of screening 
chromoendoscopy.108
Devices that allow for real-time histologic assessment of 
colonic mucosa during colonoscopy have also shown promise 
in the detection of SPs. Narrow-band imaging (NBI) with 
and without magnification are the most popular of these, and 
both have been proven to reliably differentiate adenomas with 
malignant potential from benign hyperplastic lesions.109–111 
Several groups have developed and validated standard criteria 
by which to identify SPs utilizing NBI.112,113 However, a recent 
meta-analysis did not find strong evidence for the benefit of 
image-enhanced colonoscopy for detection of SSPs, and thus, 
studies specifically designed to assess SSP detection rates are 
needed before these modalities can be widely accepted.114
More recently, a number of devices aimed at exposing 
additional colonic mucosa have been developed, such as 
wide-angled lenses and retroscopes (Figure 4). These devices 
are designed to broaden the operator’s visual field and help 
image the backs of colonic folds. Panoramic or wide-angled 
colonoscopy devices employ multiple lenses to nearly double 
the standard visual field, and a recent RCT showed significant 
decreases in adenoma miss rates over standard colonos-
copy.115 Retroscope devices provide a continuous retroflexed 
view of the colonic mucosa as the scope is withdrawn and 
may also improve detection of adenomas and SSPs.116,117
Endoscopic removal
In the absence of formal guidelines, there are limited data 
available to aid practicing gastroenterologists. However, most 
experts recommend that all SPs with the exception of small 
(<5 mm) distal HPs be removed.4,11,14,20,34 Even then, many 
suggest that these diminutive, rectosigmoid HPs be sampled 
randomly for histologic evaluation.20
SPs are notoriously challenging to resect, given their ses-
sile morphology, indistinct borders, and predominance for the 
right colon, and the rates of incomplete resection are high. 
Pohl et al found that rates of incomplete resection were much 
higher for SSPs than for conventional adenomas (31.0% vs. 
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7.2%) and that SSP histology was an independent risk factor 
for incomplete resection (RR, 3.74; 95% CI, 2.04–6.84).118 
Of most concern, nearly half of large (>10 mm) SSPs were 
incompletely resected in this study, and there is evidence 
that incomplete polypectomy plays an important role in the 
development of interval CRCs.119
The optimal strategy for the resection of SPs depends on 
the location, size, and morphology of the lesion as well as the 
skill set of the individual endoscopist and the tools available 
with him or her. For smaller lesions, cold snare polypectomy 
has been found to be safe, while allowing for appropriate his-
tologic evaluation of tissue margins.120,121 Larger lesions may 
require piecemeal resection with or without mucosal “lift-
ing” with the injection of saline or another tissue expander 
to facilitate delineation and removal.122,123
Pathologic interpretation
As the malignant potential of SPs is a relatively new concept, 
consistent pathologic interpretation remains a challenge.124 
Hetzel et al exposed significant variation in the classification 
of HPs and SSPs among practicing pathologists at a single 
academic medical center.17 In a large retrospective Canadian 
study, substantial numbers of proximal HPs (20%) and HPs 
>5 mm (17%) were reclassified as SSPs upon review by 
trained gastrointestinal pathologists, and these results were 
replicated in a recent European study.125 Importantly, mis-
classification of SPs makes interpreting older studies of SPs 
(particularly those published prior to 2008) challenging, and 
even contemporary studies may include patients with older 
pathology readings that are not consistent with contemporary 
criteria. While there is evidence that the pathologic diagnosis 
of SSPs is increasing with time,126 educational outreach and 
seamless communication between gastroenterologists and 
pathologists are needed to improve diagnostic accuracy and 
ensure appropriate management.
Surveillance
Of critical importance to the management of SPs is the 
establishment of appropriate surveillance intervals. Both the 
US Multisociety Task Force and an international consensus 
panel have outlined a detailed strategy for the management 
of HPs, SSPs, SSPDs, and TSAs20,127 (Table 2). The latest 
European guidelines include no specific recommendations 
for SPs.128 Of note, the consensus panel recommends more 
frequent surveillance in patients with proximal and/or large 
HPs, reflecting an appreciation of the aforementioned chal-
lenges in pathologic diagnosis. For patients diagnosed with 
SPS, annual colonoscopy is recommended.20 An interval of 
3–6 months is suggested for SPs requiring piecemeal resec-
tion or with positive margins on routine pathologic examina-
tion to ensure adequate resection.20,74,127
Future directions
Improving our understanding of serrated 
carcinogenesis
The genetic and epigenetic drivers of the serrated pathway 
are incompletely understood. Identifying both the cause 
and the downstream effects of CpG island methylation may 
reveal additional tumor markers and/or novel therapeutic 
approaches. Also, a better understanding of the genetic basis 
A
D
E
B
C
330°
20 40
Figure 4 Novel colonoscopic technologies.
Notes: (A) Cap-assisted colonoscopy, (B) panoramic colonoscopy being attached to standard colonoscope and demonstrating added visual fields, (C) wide-angled 
colonoscopy demonstrating improved visual field with added lenses, (D) retroscope colonoscopy through port of standard colonoscope, (E) endocuff colonoscopy.
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of SPS would undoubtedly aid in the detection, classification, 
and management of these challenging cases. As our molecular 
diagnostics improve, we may come to recognize the separate 
phenotypes of SPS as distinct clinical entities.
Optimizing detection and resection
Perhaps the first obstacle to overcome with regard to 
improving the detection of SPs is the variation that cur-
rently exists between practicing endoscopists. Operators 
should strive to meet published standards for conventional 
adenomas. Based on available data, a detection rate of at 
least 1%–2% for SSPs is reasonable.129 However, this likely 
underestimates the true prevalence of these lesions, as trials 
utilizing formal training programs and advanced endoscopic 
techniques report much higher numbers.33,130 Fecal DNA 
tests have shown promising results, but inclusion of ser-
rated pathway markers is necessary to improve their ability 
to detect advanced precancerous lesions. Further advances 
in endoscopic imaging may lead to improvement in SSP 
detection, but this remains to be seen.
There is uncertainty with respect to the optimal methods 
to resect SPs. As previously mentioned, rates of incomplete 
resection are currently above acceptable thresholds.17,94 
Clarification with regard to which lesions may benefit from 
submucosal lifting, chromoendoscopy, hot vs. cold snare 
technique, and/or underwater resection is necessary.131–133 
Whether or not certain snare designs (e.g., crescent-shaped, 
stiff, or braided wire snares) are superior to others for the 
resection of SSPs and other flat polyps is also an area where 
additional data are needed.
Clarifying surveillance intervals
Understanding the natural history of SPs is essential to out-
lining appropriate surveillance intervals. Current guidelines 
vary and are not based on robust data. Well-designed epide-
miologic studies of MSI-H, proximal, and interval CRCs may 
provide useful information about the dwell time of SPs. In 
addition, the identification of molecular and histologic fea-
tures associated with rapid progression would be invaluable.
As our power to detect even the subtlest colonic lesions 
increases, there are appropriate concerns about the added 
risk of consequent resections and surveillance. Especially 
in the arena of cancer screening, gastroenterologists must 
be careful not to upset the delicate balance between benefit 
and harm. Surveillance recommendations are fluid and likely 
to change as our understanding of serrated carcinogenesis 
improves, and this is a rapidly evolving field. Therefore, cur-
rent practice must continually be reappraised to ensure the 
optimal care of patients harboring SPs.
Conclusion
Serrated neoplasms are responsible for a third of newly diag-
nosed CRC, a disproportionate number of which are interval 
cancers and occur despite recommended screening. Despite 
Table 2 Current recommendations for surveillance intervals after colonoscopy with serrated polyps
Histology Size Number Location Guideline-recommended surveillance 
interval (years)
Consensus20 US MSTF127 European128
HP <10 mm Any Recto sigmoid 10 10 10
HP ≤5 mm ≤3 Proximal to sigmoid 10 No rec No rec
HP Any ≥4 Proximal to sigmoid 5 No rec No rec
HP >5 mm ≥1 Proximal to sigmoid 5 No rec No rec
SSP <10 mm <3 Any 5 5 No rec
SSP <10 mm ≥3 Any 3 5a No rec
SSP ≥10 mm 1 Any 3 3 No rec
SSP ≥10 mm ≥2 Any 1–3 3 No rec
SSPD Any Any Any 1–3 3 No recb
TSA <10 mm <3 Any 5 3 10
TSA ≥10 mm 1 Any 3 3 3
TSA <10 mm ≥3 Any 3 3 1–3
Combined conventional  
and serrated polyps
Any Any Any No rec No rec No rec
Serrated polyposis  
syndrome
See text See text See text 1 1 No rec
Notes: aNo specific recommendation regarding shortened interval for ≥3 SSPs. bEuropean guidelines recommend that “mixed polyps” be managed like conventional 
adenomas, which could include surveillance from 1 to 10 years based on the number and size of SSPDs.
Abbreviations: HP, hyperplastic polyp; US MSTF, US Multisociety Task Force; rec, recommendation; SSP, sessile serrated polyp; SSPD, sessile serrated polyp with dysplasia; 
TSA, traditional serrated adenoma.
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progress, pathologic misclassification and endoscopic under-
detection of SPs remain significant challenges. Innovations 
such as NBI, wide-angle colonoscopy, and fecal DNA testing 
are promising, but additional study is needed to ensure these 
technologies improve SP detection and decrease CRC inci-
dence. Future investigations should focus on understanding 
the natural history of SPs, identifying risk factors for rapid 
progression and optimizing the detection and resection of 
these lesions.
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